Outcomes of citalopram dosage risk mitigation in a veteran population

American Journal of Psychiatry

Volumn 173, Issue 9, 2016, Pages 896-902

  Rector, Thomas S ^a   Adabag, Selcuk ^a   Cunningham, Francesca ^a   Nelson, David ^a   Dieperink, Eric ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM;

ADULT; ARTICLE; COHORT ANALYSIS; DEPRESSION; DRUG DOSE REDUCTION; DRUG SAFETY; FEMALE; HEART ARRHYTHMIA; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY RATE; PRESCRIPTION; PRIORITY JOURNAL; QT PROLONGATION; RETROSPECTIVE STUDY; VETERAN; AGED; CAUSE OF DEATH; CHEMICALLY INDUCED; DOSE RESPONSE; JERVELL-LANGE NIELSEN SYNDROME; MIDDLE AGED; RISK;

ADULT; AGED; CAUSE OF DEATH; CITALOPRAM; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; JERVELL-LANGE NIELSEN SYNDROME; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK; VETERANS;

EID: 84991240936     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2016.15111444     Document Type: Article

References (28)

1. Murphy S, Roberts R: "Black box" 101: how the Food and Drug Administration evaluates,communicates, and managesdrug benefit/ risk. J Allergy Clin Immunol 2006; 117:34-39
2. US Food and Drug Administration: Guidance for Industry: Drug Safety Information: FDA's Communication to the Public, Silver Spring, Md, 2012 (http://www. fda. gov/downloads/Drugs/ guidanceComplianceRegulatory Information/Guidances/UCM295217. pdf )
3. Avorn J: Drug warnings that can cause fits: communicating risks in a data-poor environment. N Engl J Med 2008; 359:991-994
4. Furedi A: The public health implications of the 1995 'pill scare'. Hum Reprod Update 1999; 5:621-626
5. FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). US Food and Drug Administration, Silver Spring, Md, 2012 (http:// www. fda. gov/Drugs/DrugSafety/ucm269086. htm)
6. Vieweg WVR, Hasnain M, Howland RH, et al: Citalopram, QTc interval prolongation, and torsade de pointes. How should we apply the recent FDA ruling? Am J Med 2012; 125:859-868
7. KellerMB: Citalopram therapy for depression: a review of 10 years of European experience and data from U. S. clinical trials. J Clin Psychiatry 2000; 61:896-908
8. Adli M, Baethge C, Heinz A, et al: Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? a systematic review. Eur Arch Psychiatry Clin Neurosci 2005; 255:387-400
9. Musselman DL, Evans DL, Nemeroff CB: The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment. Arch Gen Psychiatry 1998; 55:580-592
10. Tiihonen J, Lönnqvist J, Wahlbeck K, et al: Antidepressants and the risk of suicide, attempted suicide, and overall mortality in a nationwide cohort. Arch Gen Psychiatry 2006; 63:1358-1367
11. Yu AP, Xie J, Bensimon A, et al: Economic consequence of switching to citalopram after its generic entry for adult patients with major depressive disorder (MDD) treated with escitalopram: a 6-month retrospective study. J Med Econ 2010; 13:599-609
12. Zivin K, Yosef M, Miller EM, et al: Associations between depression and all-cause and cause-specific risk of death: a retrospective cohort study in the Veterans Health Administration. J Psychosom Res 2015; 78:324-331
13. Quan H, Sundararajan V, Halfon P, et al: Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005; 43:1130-1139
14. Woosley RL: Drugs that prolong the Qt interval and/or induce Torsades de Pointes. (www. azcert. org/medical-pros/drug-lists/ printable-drug-list. cfm)
15. Zanger UM, Schwab M: Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 2013; 138:103-141
16. Sohn MW, Arnold N, Maynard C, et al: Accuracy and completeness of mortality data in the Department of Veterans Affairs. Popul Health Metr 2006; 4:2
17. Schneeweiss S, Patrick AR, SolomonDH,et al: Variation in the risk of suicide attempts and completed suicides by antidepressant agent in adults: a propensity score-adjusted analysis of 9 years' data. Arch Gen Psychiatry 2010; 67:497-506
18. VanCott AC, Cramer JA, Copeland LA, et al: Suicide-related behaviors in older patients with new anti-epileptic drug use: data from the VA hospital system. BMC Med 2010; 8:4
19. Miller M, Swanson SA, Azrael D, et al: Antidepressant dose, age, and the risk of deliberate self-harm. JAMA Intern Med 2014; 174:899-909
20. Hennessy S, Leonard CE, Freeman CP, et al: Validation of diagnostic codes for outpatient-originating sudden cardiac death and ventricular arrhythmia in Medicaid and Medicare claims data. Pharmacoepidemiol Drug Saf 2010; 19:555-562
21. Zambon A, Polo Friz H, Contiero P, et al: Effect of macrolide and fluoroquinolone antibacterials on the risk of ventricular arrhythmia and cardiac arrest: an observational study in Italy using case-control, case-crossover and case-time-control designs. Drug Saf 2009; 32: 159-167
22. De Bruin ML, Hoes AW, Leufkens HGM:QTc-prolonging drugs and hospitalizations for cardiac arrhythmias. Am J Cardiol 2003; 91: 59-62
23. Austin PC: Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med 2009; 28:3083-3107
24. Stürmer T, Schneeweiss S, BrookhartMA,et al: Analytic strategies to adjust confounding using exposure propensity scores and disease risk scores: nonsteroidal antiinflammatory drugs and short-term mortality in the elderly. Am J Epidemiol 2005; 161:891-898
25. Sauer BC, Brookhart MA, Roy J, et al: A review of covariate selection for non-experimental comparative effectiveness research. Pharmacoepidemiol Drug Saf 2013; 22:1139-1145
26. McKean AJ, Sola CL, Galardy C, et al: Reconciling the risk of QT interval prolongation in antidepressants. Pharmacoepidemiol Drug Saf 2012; 21:329-330
27. Castro VM, Clements CC, Murphy SN, et al: QT interval and antidepressant use: a cross sectional study of electronic health records. BMJ 2013; 346:f288
28. Zivin K, Pfeiffer PN, Bohnert ASB, et al: Evaluation of the FDA warning against prescribing citalopram at doses exceeding 40 mg. Am J Psychiatry 2013; 170:642-650